ClinicalTrials.gg
CompletedNCT07344558Updated Jul 22, 2026

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis

A Phase 1 interventional study of MNKD-201(Nintedanib DPI) and Placebo in Idiopathic Pulmonary Fibrosis (IPF), sponsored by Mannkind Corporation. Completed at 9 sites in United States. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Mannkind Corporation · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States — 37 open to participants now, 51 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · United States.

Enrollment
138th of 188
27 · median 61
Started
2025
with 10 others
Phase 1
39 of 236
3 open now
Registered
225th of 236
by date

Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, this one is the 138th largest by enrollment of the 188 interventional ones that give a count, is one of 11 that started in 2025, is one of 39 in phase 1, and was the 225th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

37 of the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, or all of them as a file.
02

Study summary

MKC-NI-002 is a Phase 1b, randomized, double-blind, placebo-controlled study of nintedanib inhalation powder (MNKD-201) in patients with Idiopathic Pulmonary Fibrosis (IPF). The trial consists of Multiple Ascending Doses (MAD) with the primary objective to evaluate safety, tolerability and pharmacokinetics (PK) of MNKD-201 compared to placebo in patients with IPF.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis (IPF)

Keywords

  • Nintedanib
  • dry powder inhalation
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is ≥40 to ≤85 years of age at the time of signing the form.
  2. Diagnosis of IPF
  3. Either treatment-naive or is currently on background pirfenidone or nerandomilast on a stable dose for at least 3 months prior to Screening.
  4. Has FVC >45% of predicted of normal, as determined by the central spirometry reader, during Screening.
  5. DLCO corrected for [Visit 1] ≥40% of predicted of normal, within 12 months of Screening. If no historical DLCO is available prior to Screening, this is to be done during Screening and read locally.
  6. Has a body weight >40 kg (>88 lbs.) at Screening.
  7. For female participants of , agreement to use acceptable
  8. For male participants who can father a child and are having intercourse with females of childbearing potential, agreement to use a protocol-recommended method of contraception
  9. Is capable of performing spirometry, as required by the study procedures and ATS guidelines.
  10. CT chest within 2 years of Screening, consistent with an IPF diagnosis, per investigator assessment.

Exclusion criteria

Exclusion Criteria:

  1. Known explanation for interstitial lung disease, including but not limited to radiation, sarcoidosis, pneumonitis, and bronchiolitis obliterans organizing pneumonia.
  2. Diagnosis of any connective tissue disease, including but not limited to scleroderma/systemic sclerosis, polymyositis/dermatomyositis, systemic lupus erythematosus, and rheumatoid arthritis, regardless of whether or not it is presumed to be related to their pulmonary fibrosis diagnosis.
  3. Major extrapulmonary physiological restriction (e.g., chest wall abnormality, large pleural effusion), as determined by the investigator.
  4. Significant Cardiovascular diseases
  5. Recent systemic infection within 4 weeks before the Screening visit or symptomatic viral or bacterial infection at time of Screening.
  6. Prior hospitalization for confirmed coronavirus disease 2019 (COVID-19), acute exacerbation of IPF or any lower respiratory tract infection within 3 months of Screening.
  7. Has a history of asthma, with the exception of resolved childhood asthma.
  8. Has known obstructive lung disease
  9. (ALT), aspartate aminotransferase (AST), or total >1.5 times the (ULN) during Screening.
  10. Advanced liver and kidney function.
  11. Current or recent (within 30 days of Screening) use of nintedanib.
  12. Use of prednisone >10 mg/day within 1 month prior to Screening, or other significant
  13. Active lung cancer (primary or ) or any cancer requiring chemotherapy or radiation therapy within 3 years, except appropriately treated non-melanoma skin cancer, localized non-malignant prostate cancer, or in situ carcinoma of uterine cervix.
  14. Has participated in another clinical study of a new chemical entity, new device, or a prescription medicine within the 1 month before Screening
  15. Current alcohol, medication, or illicit drug abuse
  16. Has lost more than 400 mL blood, e.g., as a blood donor, or donor of blood products, during the 3 months prior to Screening.
  17. Has received a within the 3 months prior to the first dose of study drug.
  18. Smokes (any substance including electronic cigarettes and marijuana) within 3 months prior to Screening or is an ex-cigarette smoker who gave up \<1 year ago.
  19. Has oxygen requirement of > 6 liters/min at rest.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Cohort 1: MNKD-201 Target Dose or placebo

    Participants will receive a target dose of MNKD-201 (Nintedanib DPI) or placebo, administered via oral inhalation three times daily for 7 days

    Drug: MNKD-201(Nintedanib DPI)

  • Experimental
    Cohort 2: MNKD-201 High Dose or placebo

    Participants will receive a high dose of MNKD-201 (Nintedanib DPI) or placebo, administered via oral inhalation twice daily for 7 days

    Drug: MNKD-201(Nintedanib DPI)

  • Placebo comparator
    Placebo

    Participants will receive matching placebo across both cohorts of the study

    Drug: Placebo

Interventions

  • DrugMNKD-201(Nintedanib DPI)

    MNKD-201 is a dry powder nintedanib formulation for oral inhalation.

  • DrugPlacebo

    The placebo control in this study is an empty cartridge without any powder.

06

What researchers measure

Primary outcomes

  1. (Cohort 1) Events of Bronchospasm

    The within-treatment number and proportion of participants with events of bronchospasm (e.g., treatment emergent adverse events \[TEAE\] immediately after inhalation of wheezing or chest tightness)

    Time frame: Up to Day 7

  2. (Cohort 2) Events of Bronchospasm

    The within-treatment number and proportion of participants with events of bronchospasm (e.g., treatment emergent adverse events \[TEAE\] immediately after inhalation of wheezing or chest tightness)

    Time frame: Up to Day 7

  3. (Cohort 1) Changes in FEV1 (mL) from pre-dose to post-dose

    The within-treatment number and proportion of participants with changes in FEV1 from pre-dose to any time post-dose

    Time frame: Up to Day 7

  4. (Cohort 2) Changes in FEV1 (mL) from pre-dose to post-dose

    The within-treatment number and proportion of participants with changes in FEV1 from pre-dose to any time post-dose

    Time frame: Up to Day 7

  5. (Cohort 1) Changes in FEV1 / FVC ratio from pre-dose to post-dose

    The within-treatment number and proportion of participants with changes in FEV1/FVC ratio from pre-dose to any time post-dose

    Time frame: Up to Day 7

  6. (Cohort 2) Changes in FEV1 / FVC ratio from pre-dose to post-dose

    The within-treatment number and proportion of participants with changes in FEV1/FVC ratio from pre-dose to any time post-dose

    Time frame: Up to Day 7

  7. (Cohort 1) Rate of Study Drug Discontinuations

    The within-treatment number and proportion of participants with study drug dose discontinuations

    Time frame: Up to Day 7

  8. (Cohort 2) Rate of Study Drug Discontinuations

    The within-treatment number and proportion of participants with study drug dose discontinuations

    Time frame: Up to Day 7

  9. (Cohort 1) Rate of Study Drug Dose Reductions

    The within-treatment number and proportion of participants with study drug dose reductions

    Time frame: Up to Day 7

  10. (Cohort 2) Rate of Study Drug Dose Reductions

    The within-treatment number and proportion of participants with study drug dose reductions

    Time frame: Up to Day 7

  11. (Cohort 1) Rate of Treatment Emergent Adverse Events (TEAEs)

    The within-treatment number and proportion of participants with TEAEs overall and by severity, relationship to study drug, and outcome

    Time frame: Up to Day 7

  12. (Cohort 2) Rate of Treatment Emergent Adverse Events (TEAEs)

    The within-treatment number and proportion of participants with TEAEs overall and by severity, relationship to study drug, and outcome

    Time frame: Up to Day 7

  13. (Cohort 1) Rate of Treatment Related Adverse Events (TRAEs)

    The within-treatment number and proportion of participants with TRAEs overall and by severity and outcome

    Time frame: Up to Day 7

  14. (Cohort 2) Rate of Treatment Related Adverse Events (TRAEs)

    The within-treatment number and proportion of participants with TRAEs overall and by severity and outcome

    Time frame: Up to Day 7

  15. (Cohort 1) Rate of Serious Adverse Events (SAEs)

    The within-treatment number and proportion of participants with SAEs overall and by severity, relationship to study drug, and outcome

    Time frame: Up to Day 7

  16. (Cohort 2) Rate of Serious Adverse Events (SAEs)

    The within-treatment number and proportion of participants with SAEs overall and by severity, relationship to study drug, and outcome

    Time frame: Up to Day 7

Secondary outcomes

  1. Determine the maximum tolerated dose (MTD) of MKND-201 in patients with IPF

    MTD within the tested MNKD-201 dose range

    Time frame: Up to Day 7

07

Study locations

9 sites
  • VALDI
    Fresno, California 93720, United States
  • Palmtree Clinical Research
    Palm Springs, California 92262, United States
  • Innova Pharma Research
    Doral, Florida 33172, United States
  • New Life Medical Research
    Hialeah, Florida 33012, United States
  • New Access Research and Medical Services
    Miami, Florida 33186, United States
  • Southeastern Research Center
    Winston-Salem, North Carolina 27103, United States
  • Low Country Research
    Charleston, South Carolina 29406, United States
  • Metroplex Pulmomary & Sleep Center
    McKinney, Texas 75069, United States
  • Pulmonary Medicine Consultants
    McKinney, Texas 75071, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Jun 2026, 5 months.

Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 5 months is below that.

Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2026
First posted
Jan 15, 2026
StartActual
Dec 22, 2025
Primary completionActual
Jun 17, 2026
CompletionActual
Jun 17, 2026
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07344558
Responsible party
Sponsor
First posted
Jan 15, 2026
Start date
Dec 22, 2025
Primary completion
Jun 17, 2026
Completion
Jun 17, 2026
Last update
Jul 22, 2026

Study contacts

Wassim Fares, MD, MSc, FCCP
study director · Mannkind Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion